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JPG@dadlnet.dkAbstractCardiovascular risk assessment remains difficult in elderly patients. We examined whether
chromogranin A (CgA) measurement in plasma may be valuable in assessing risk of death in
elderly patients with symptoms of heart failure in a primary care setting. A total of 470
patients (mean age 73 years) were followed for 10 years. For CgA plasma measurement,
we used a two-step method including a screening test and a confirmative test with
plasma pre-treatment with trypsin. Cox multivariable proportional regression and
receiver-operating curve (ROC) analyses were used to assess mortality risk. Assessment of
cardiovascular mortality during the first 3 years of observation showed that CgA
measurement contained useful information with a hazard ratio (HR) of 5.4 (95% CI 1.7–16.4)
(CgA confirm). In a multivariate setting, the corresponding HR was 5.9 (95% CI 1.8–19.1).
When adding N-terminal proBNP (NT-proBNP) to the model, CgA confirm still possessed
prognostic information (HR: 6.1; 95% CI 1.8–20.7). The result for predicting all-cause
mortality displayed the same pattern. ROC analyses in comparison to NT-proBNP to identify
patients on top of clinical variables at risk of cardiovascular death within 5 years of follow-up
showed significant additive value of CgA confirm measurements compared with NT-proBNP
and clinical variables. CgA measurement in the plasma of elderly patients with symptoms of
heart failure can identify those at increased risk of short- and long-term mortality.icen
.0 UEndocrine Connections
(2014) 3, 47–56IntroductionHeart failure is a syndrome comprising cardiac dysfunc-
tion and neurohumoral activation. Medical treatment
aims at neutralizing hormonal actions by blocking
receptors or inhibiting activation of vasoconstrictive
substances. In particular, blockade of the concomitant
sympathetic activation via adrenergic receptors has
reduced mortality and morbidity in chronic heart
failure patients.Plasma adrenalin and noradrenalin are dominantly
secreted from the adrenal glands. Another substance
secreted from the adrenal medulla is chromogranin A, or
CgA (1). CgA measurement in plasma has a central role in
the diagnosis and treatment follow-up of neuroendocrine
tumors, since these tumors often produce vast amounts of
CgA (2, 3, 4). In the cardiological setting, CgA measure-
ment has only been explored in small patient cohorts withsed under a Creative Commons
nported License.
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Research J P Goetze et al. Chromogranin A in heart failure 2–10 3 :48acute coronary syndrome or heart failure (5, 6, 7, 8, 9).
Interestingly, a few reports have suggested that the heart
muscle itself produces CgA that may contribute to the
plasma pool (10, 11). For now, CgA plasma measurement
as a biomarker in heart failure is still only examined in
highly selected patients and cannot be recommended for
general use (12). Moreover, methodological problems on
CgA measurement have hampered the general use of CgA
as a biomarker, because CgA processing is extensive,
variable, and harbors a plethora of fragments.
In the present study, we examined a cohort of elderly
patients with symptoms suggestive of heart failure, i.e.
tiredness, dyspnea, and/or edema, in the primary care
setting. For CgA plasma measurement, we used state-
of-the-art analyses (13) that measure a well-defined
epitope in the CgA protein (screen test), and an extended
version of the analysis that quantitates the total amount of
CgA products in blood irrespective of post-translational
processing (confirm test).Subjects and methods
The design of the study has previously been published
(14, 15). The patient population consisted of patients,
65–87 years of age, recruited from a primary health center
with symptoms of heart failure (dyspnea, tiredness,
and/or peripheral edema). A cardiologist reviewed all
records of patients with the listed symptoms and then
met all patients, performed a clinical examination and a
2D echocardiography, and established new patient
records. The revised illnesses in the patients have also
been reported previously (16). Patients in whom heart
failure could not be excluded were invited to participate
in the study. All participants were included in 1996 and
were followed for 13 years. The evaluation of the markers,
however, covered a follow-up period of 10 years based on
blood samples collected at study inclusion. During the
follow-up period, all mortality was registered and data
were recorded from death certificates or autopsy records.
Written, informed consent was obtained from all patients
at inclusion, and the study protocol was approved by the
Regional Ethical Review Board in Linko¨ping.Echocardiography
Doppler echocardiographic examinations (Accuson XP-
128c) were performed with participants in the left lateral
position. Normal left ventricular systolic function was
defined as EF R50%: severely impaired systolic function
was defined as EF !30% (17, 18). For assessment ofhttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0017
 2014 The authors
Published by Bioscientifica Ltddiastolic function, mitral flow E:A ratios and pulmonary
venous flow patterns were analyzed and compared with
age-adjusted reference values.Biochemical analyses
N-terminal proBNP (NT-proBNP or proBNP 1–76) was
measured on the Elecsys 2010 platform (Roche Diagno-
stics). This assay uses two polyclonal antibodies directed
against amino acid sequences 1–21 and 39–50 respect-
ively. Total assay CV was 4.8% at 220 ng/l and 2.1% at
4254 ng/l (nZ70).
CgA was measured with two assays. First, an in-house
immunoassay using antibodies raised against the 340–348
CgA fragment was used as screen test. Plasma was then
incubatedwith trypsin to cleave CgA andCgA fragments at
dibasic cleavage sites (13). Moreover, this enzymatic
treatment removes possible interference from plasma
proteins (19, 20). The same monospecific RIA was then
employed again and thus quantitated the total CgA
concentration in plasma. The extended test was used as a
confirmatory test in the present study. This assay has
previously been employed successfully for the diagnosis
and follow-up of carcinoid tumors (21). The interassay
precision at 60 pmol/l is !20% (JP Goetze, LM Hilsted,
JF Rehfeld&UAlehagen, 2013, unpublished observations).Statistical analyses
Descriptive data are presented as percentages or mean and
S.D. In the case of continuous variables, comparative
analyses were performed using the Student’s unpaired
two-sided t-test, whereas the c2 test was used for discrete
variables. Cox proportional hazard regression analyses as
well as a Kaplan–Meier analysis were used to analyze the
risk of mortality during the follow-up period. Censored
patients were those still alive at end of the study period or
who had died of other causes than cardiovascular disease.
Completed patients comprised those who had died due to
cardiovascular disease.
The assumption of proportionality was tested as long
follow-up. As the assumption was not fulfilled, we chose to
present mortality data in two steps: short-term mortality
with a follow-up time of 3 years and long-term mortality
with a follow-up time of up to 10 years. To evaluate the
possible additive prognostic effects of the biomarkers in
multivariate analysis, Cox proportional regression
analyses were carried out. Three different models have
been used: model I consisted of a univariate evaluation,
model II consisted of a multivariate evaluation in whichThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Research J P Goetze et al. Chromogranin A in heart failure 3–10 3 :49clinical variables that could influence the risk of cardio-
vascular mortality were included. In model III, all clinical
variables frommodel II were included and NT-proBNP was
added to the model.
In order to evaluate specificity and sensitivity,
receiver-operating curve (ROC) analyses have been per-
formed by using the method advised by DeLong et al. (22).
To evaluate a possible significant difference between two
ROC curves, the contrast between them has been
evaluated. A clinical prognostic index was developed
based on the b coefficients obtained from the Cox
proportional hazard regression analyses. Three models
were tested in the ROC analyses: model I, clinical variables
only; model II, clinical variablesCNT-proBNP, and model
III, clinical variablesCNT-proBNPCCgA confirm. The
clinical variables included were as follows: NYHA
functional class III, Hb !120 g/l, diabetes, male gender,
and ischemic heart disease. The area under curve was
calculated for the three models. For model I, a sensitivi-
ty/specificity of 56 and 85% was chosen; for model II, the
corresponding values were 71 and 77%; and finally for
model III, the corresponding values were 73 and 76%.
A P value !0.05 was considered statistically significant.
All data were analyzed using standard software packages
(Statistica v. 12.0, Statsoft, Inc., Analyse-it v.3.53;
Analyse-it Software Ltd, Tulsa, OK, USA).Results
An elderly population with a mean age of 73 years and
with an equal distribution between males/females was
evaluated. The basic characteristics are presented in
Supplementary Table 1, see section on supplementary
data given at the end of this article. All patients were
presented with dyspnea, tiredness, and/or peripheral
edema. The study population was followed for 13 years
(median 4725 days, range 242–5112). The first patient was
included in January 1996, and the last follow-up date was
December 31, 2009. As patients in treatment with proton
pump inhibitors display increased plasma concentrations
of CgA due to increased production of CgA from gastric
enterochromaffin-like cells, it is important to identify
patients with such treatment. In our population, only a
small fraction was on treatment with proton pump
inhibitors (nZ3; 0.6%) and none of the three had high
levels of CgA. These patients were, therefore, included in
the calculations.
During the observation period, 226 patients (48%)
suffered all-cause mortality and 146 patients (31%)
cardiovascular mortality. Notably, no patient was losthttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0017
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Published by Bioscientifica Ltdduring follow-up. The part that survived all-cause
mortality during the follow-up period had a median
observation period of 4923 days (range 4773–5112),
whereas those that did not survive during the follow-up
period had a median observation period of 2723 days
(range 242–5018). The distribution of cardiovascular
mortality in the different quartiles of proBNP and CgA
screen and confirm is shown in Supplementary Table 2, see
section on supplementary data given at the end of this
article. We chose to use quartiles in order to apply more
than one cutoff value, as for example by usingmedians. An
increase in cardiovascular mortality was found as a
function of increasing quartiles. A similar pattern,
although different in sizes, was seen for all biomarkers.
The greatest difference in mortality between the quartiles
could, however, be seen in the NT-proBNP biomarker. In
the cardiovascular mortality evaluation over 10 years, the
difference in mortality between 1st and 4th quartiles in
CgA confirm test was 24.2%, whereas the difference in
plasma NT-proBNP concentration was 41.9%. Smaller
differences between 1st and 4th quartiles were found
with the CgA screen test.Prognostic information
When assessing the prognostic information regarding all-
cause mortality during the first 3 years of observation, we
found (model I; univariate regression) that CgA confirm
testing contained significant prognostic information with
a hazard ratio (HR) of 3.49 (95% CI 1.51–8.10) as shown in
Supplementary Table 3, see section on supplementary data
given at the end of this article. In model II, where clinical
variables were added to the model, the CgA confirm test
still contained information with HR of 3.48 (95% CI 1.42–
8.53). After adding the gold standard biomarker for heart
failure (NT-proBNP) into the model (model III), the CgA
confirm test still exhibited significant and independent
prognostic information (HR 3.61, 95% CI 1.42–9.15). The
CgA screen test did not, however, exhibit any significant
information in this setup. Analysis for cardiovascular
mortality during the same time frame showed a similar
pattern, i.e., significant HRs for the CgA confirm test in
models I, II, and III (shown in Table 1). The HRs were even
higher, but the CIs were also wider due to small samples.
Analyzing the prognostic information for all-cause
mortality in the time frame up to 10 years, CgA screen
and confirm testing exhibited significant prognostic
information in model I (Table 2). In the multivariate
setting in model II, only CgA confirm test could exhibit
significant prognostic information, which persisted also inThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 1 Cox proportional hazard regression analysis of risk of cardiovascular mortality in three regression models during 3 years of
follow-up in the study population
Biomarker
Model I Model II Model III
Hazard ratio 95% CI P value Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Chromogranin
A screenO
median
0.94 0.36–2.43 0.89 0.74 0.27–2.00 0.55 0.74 0.27–2.01 0.56
Chromogranin
A confirmO
median
5.35 1.74–16.43 0.003 5.90 1.82–19.06 0.003 6.10 1.80–20.71 0.004
NT-proBNPO
median
– – – – – – 11.03 2.38–51.09 0.002
Model I, univariate analysis; model II, model adjusted for hypertension, ischemic heart disease, eGFR!60 ml/min, male gender, smoking habit, peripheral
edema, rales, ageO80 years, Hb!120 g/l; model III, all clinical variables from model IIC4th quartile of NT-proBNP. Median of chromogranin A screen test:
65 pmol/l; median of chromogranin A confirm test: 531 pmol/l; median of NT-proBNP: 220 pmol/l. Each of the two biomarkers were evaluated one at a time
in the different models. NT-proBNP evaluation illustrated in model III is obtained from the analysis including chromogranin A confirm test.
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Research J P Goetze et al. Chromogranin A in heart failure 4–10 3 :50competition with NT-proBNP in model III (HR 1.44, 95%
CI 1.05–1.98). Finally, when analyzing the cardiovascular
mortality during the same time frame (Table 3), it was
noted that both the CgA screen and confirm measure-
ments reached significant prognostic information in
model I, and that CgA confirm measurements reached
significant prognostic information both inmodel II and III
(HR 1.77, 95% CI 1.21–2.60, and HR 1.66, 95% CI 1.13–
2.45 respectively).
Analyzing the study population by Kaplan–Meier
analyses regarding all-cause mortality during 10 years of
follow-up distributed in different combinations of groups
of CgA confirm test and NT-proBNP when applying the
median concentration as cut-point, we found that an
increasing number of patients did not survive as the
plasma concentration increased, fewest in group 4 whereTable 2 Cox proportional hazard regression analysis of risk of al
follow-up in the study population
Biomarker
Model I
Hazard ratio 95% CI P value Hazard ratio
Chromogranin
A screenO
median
1.47 1.09–1.98 0.01 1.31
Chromogranin
A confirmO
median
1.72 1.28–2.32 0.0003 1.50
NT-proBNPO
median
– – – –
Model I, univariate analysis; model II, model adjusted for hypertension, ischem
edema, rales, ageO80 years, Hb!120 g/l; model III, all clinical variables from m
65 pmol/l; median of chromogranin A confirm test: 531 pmol/l; median of NT-pr
time in the different models. NT-proBNP evaluation illustrated in model III is ob
http://www.endocrineconnections.org
DOI: 10.1530/EC-14-0017
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Published by Bioscientifica Ltdboth biomarkers were above the cut-point (Fig. 1). Also,
only w40% of the patients in that group were still alive
after 10 years. Figure 2 shows the cardiovascular mortality
during 10 years of follow-up distributed in different
combinations of groups of CgA confirm test and
NT-proBNP when applying the median concentration as
cut-point; an increase in mortality between the groups 3
and 4 in relation to groups 1 and 2 could be seen and most
clearly in group 4, where both the plasma markers were
above the cut-point. In this group, only w45% were still
alive after 10 years.
In all multivariate evaluations including NT-proBNP
in the setting (model III), the CgA confirm test contained
significant and independent prognostic information
besides that of the other variables, including NT-proBNP,
the standard biomarker for heart failure. Finally, ROCl-cause mortality in three regression models during 10 years of
Model II Model III
95% CI P value Hazard ratio 95% CI P value
0.97–1.78 0.08 1.27 0.94–1.72 0.13
1.09–2.05 0.01 1.44 1.05–1.98 0.02
– – 2.06 1.47–2.87 !0.0001
ic heart disease, eGFR!60 ml/min, male gender, smoking habit, peripheral
odel IIC4th quartile of NT-proBNP. Median of chromogranin A screen test:
oBNP: 220 pmol/l. Each of the two biomarkers has been evaluated one at a
tained from the analysis including chromogranin A confirm test.
This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 3 Cox proportional hazard regression analysis of risk of cardiovascular mortality in three regression models during 10 years
of follow-up in the study population
Biomarker
Model I Model II Model III
Hazard ratio 95% CI P value Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Chromogranin
A screenO
median
1.53 1.06–2.20 0.02 1.34 0.92–1.94 0.12 1.27 0.88–1.84 0.21
Chromogranin
A confirmO
median
2.15 1.50–3.08 !0.0001 1.77 1.21–2.60 0.003 1.66 1.13–2.45 0.01
NT-proBNPO
median
– – – – – – 2.84 1.85–4.36 !0.0001
Model I, univariate analysis; model II, model adjusted for hypertension, ischemic heart disease, eGFR!60 ml/min, male gender, smoking habit, peripheral
edema, rales, ageO80 years, Hb!120 g/l; model III, all clinical variables from model IIC4th quartile of NT-proBNP. Median of chromogranin A screen test:
65 pmol/l; median of chromogranin A confirm test: 531 pmol/l; median of NT-proBNP: 220 pmol/l. Each of the two biomarkers has been evaluated one at a
time in the different models. NT-proBNP evaluation illustrated in model III is obtained from the analysis including chromogranin A confirm test.
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Research J P Goetze et al. Chromogranin A in heart failure 5–10 3 :51curve analyses of the ability of CgA measurements in
comparison to NT-proBNP on top of some well-known
clinical variables were performed in three models. In
model I, only clinical variables were performed to identify
patients who are at risk of cardiovascular death within the
3 years of follow-up (Fig. 3). In model II, NT-proBNP was
added to the clinical variables, and finally in model III,
CgA confirm was added to clinical variablesCNT-proBNP.
From the AUC analyses, a significant additive prognostic
information could be obtained by adding CgA confirm
measurements on top of NT-proBNP (AUC: 0.84, 95% CI
0.77–0.90 vs AUC: 0.79, 95% CI 0.71–0.87). The difference
in AUC betweenmodel II and III was significant, PZ0.008.
In order to evaluate what this information could result in,
we analyzed all patients that died within 5 years of
cardiovascular death. Applying model I, 25/45 (56%)
could be identified. Applying model II, 32/45 (71%) of
the deceased patients could be identified: if applying
model III, 36/45 (80%) of the deceased patient could be
identified. The same evaluation of cardiovascular
mortality on a 3-year-follow-up period gave the following
information: model I 10/17 (59%), model II 12/17 (72%),
and finally model III 14/17 (82%). Thus, addition of CgA
was associated with a 10% increase in identifying patients
at risk of cardiovascular mortality.Discussion
The present study shows that CgA measurement in elderly
patients presenting with symptoms of heart failure can
identify those at increased risk of both short- and
long-term mortality. By using an assay that measures all
forms of CgA in plasma, accurate quantitation could
be achieved that contains information beyond a ‘goldhttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0017
 2014 The authors
Published by Bioscientifica Ltdstandard’ risk marker in heart failure: thus, the data
suggest for the first time that CgA plasma measurement
may be a general risk marker in elderly patients. As our
cohort consists of patients with unspecific symptoms
suggestive of heart failure, of which only 12% reached an
actual heart failure diagnosis on echocardiography, our
data thus extend from former reports on selected patients
with established heart failure (5, 9).
In the Cox proportional regression analyses it is clear
that the CIs are wide for the CgA confirm measurements,
which is why the actual figures of the HR should be
interpreted with caution. We have, however, included the
measurements of NT-proBNP in model III in the tables to
illustrate that by use of the median plasma concentration
as cut-point in this study population, even this biomarker
– the most well-known biomarker in heart failure
evaluations – the CIs obtained are even wider than those
for the CgA confirm measurements. From the evaluation,
CgA confirm evaluations have significant and indepen-
dent prognostic information that goes beyond that of
NT-proBNP, a finding that also was noted in the
ROC analysis.
CgA measurement in cardiac patients has only been
pursued in selected patient cohorts, mostly with ischemic
heart disease (acute coronary syndromes) (5, 6, 7, 8, 9). In
these patients, CgA measurement contained prognostic
information on risk of death, which prompted us to test
CgA measurement in a different cohort. Notably, the
present study is based on elderly patients presenting with
unspecific symptoms of heart failure in a primary setting,
where most patients will be handled. Also, our study with
no patients lost during the 13 years’ follow-up allows us to
conclude without bias. The study setup thus goes beyond
the measurement of, for instance, left ventricular systolicThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Figure 1
Kaplan–Meier analysis illustrating the distribution of all-cause mortality
expressed as different combinations of level above vs below median
concentration of chromogranin A confirm test and NT-proBNP in the study
population during 10 years of follow-up. Censored patients were patients
still alive at end of the study period. Completed patients were patients who
had died due to all-cause mortality. Group 1: NT-proBNP!medianC
chromogranin A confirm!median; Group 2: NT-proBNPOmedianC
chromogranin A confirm!median; Group 3: NT-proBNP!medianC
chromogranin A confirmOmedian; and Group 4: NT-proBNPOmedianC
chromogranin A confirmOmedian.
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Research J P Goetze et al. Chromogranin A in heart failure 6–10 3 :52function and is rather based on patient’ common
symptoms such as tiredness, dyspnea, and/or peripheral
edema. We believe that such a design in itself has an
important value to clinicians when employing plasma
markers concerning risk. For now, we conclude that CgA
plasma measurement by using the new CgA measurement
assay in heart failure patients is useful as earlier suggested
(12), and that the marker can even be applied in patients
with symptoms suggestive of the condition.
CgA in plasma is a complex system of peptides (1).
The intact CgA protein acts as a precursor that is
processed before and after cellular release to multiple
fragments, some of which are suggested to have
biological activity (23). The many fragments severely
challenge the choice of method for measurement.
Moreover, measuring the selected epitope (sequence
340–348) after tryptic cleavage allows for quantitationhttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0017
 2014 The authors
Published by Bioscientifica Ltdof the total molar amount of translational products in
plasma (for review, please see reference (24)). In the
present report, we have used both methods as a screen
and a confirm test respectively. Thus, the plasma
measurements report accurately on CgA concentrations
in plasma, which not all CgA assays do. In this context,
we recently examined diagnostic immunoassays for a
more well-defined plasma marker, gastrin (25). The
results showed that more than half of the assays were
inaccurate to an extent, from which the diagnosis of
malignant gastrinoma was missed. We therefore rec-
ommend using validated CgA assays with precise knowl-
edge of the measured epitope.
CgA has been shown to be produced in the heart itself
(10, 11). For long, it has been known that the heart
produces and secretes noradrenaline (26); in fact, the
earliest hypotheses on the endocrine heart stem from thisThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Complete  Censored
Group  1
Group  2
Group  3
Group  4
0 500 1000 1500 2000 2500 3000 3500 4000 4500
Time (days)
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Cu
m
u
la
tiv
e
 p
ro
po
rti
on
 s
ur
vi
vi
ng
Patients at risk
Inkl Day 700 Day 1400 Day 2100 Day 2800 Day 3500
Group 1 159 159 158 149 135 130
Group 2 129 127 117 107 94 76
Group 3 76 73 70 63 60 54
Group 4 105 101 83 71 62 49
Figure 2
Kaplan–Meier analysis illustrating the distribution of cardiovascular
mortality expressed as different combinations of level above vs below
median concentration of chromogranin A confirm test and NT-proBNP in
the study population during 10 years of follow-up. Censored patients were
patients still alive at end of the study period or who had died of other
reasons than cardiovascular disease. Completed patients were patients
who had died due to cardiovascular mortality. Group 1: NT-proBNP !
medianCchromogranin A confirm! median; Group 2: NT-proBNPO
medianCchromogranin A confirm!median; Group 3: NT-proBNP!
medianCchromogranin A confirmOmedian; and Group 4: proBNPO
medianCchromogranin A confirmOmedian.
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Research J P Goetze et al. Chromogranin A in heart failure 7–10 3 :53observation (27).However, the contributionof cardiacCgA
to plasma is more debatable, as for instance the adrenal
medulla and thegastrointestinal tract aremajor sitesofCgA
production. Our results do not answer the question of
organ specificity to the measured CgA in the patient
plasma, but we note that CgA measurement still proves
valuable even when including proBNP measurement in
the analyses. Thus, we suggest that increased CgA may
dominantly represent sympathetic activity in the
adrenal medulla and therefore relate to general stress
in disease. However, further experimental studies are
now warranted to identify the major source of the CgA
in patients.
In the European Society of Cardiology Guidelines
2008 on the diagnosis and handling of heart failurehttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0017
 2014 The authors
Published by Bioscientifica Ltdpatients, it is stated that in those with signs/symptoms
of heart failure and NT-proBNP plasma concentrations
%400 ng/l, the possibility of heart failure should be
further considered. In the subpopulation, in which a
corresponding proBNP concentration was obtained and a
low risk of mortality was to be expected according to the
NT-proBNP concentration, we analyzed patients with CgA
measurements greater than median plasma concentration
in a univariate Cox proportional hazard regression
including 3 years of observation. In spite of a low
NT-proBNP concentration, a significant increase in the
risk of all-cause mortality was identified with CgA confirm
measurement (HR 4.17, 95% CI 1.04–16.69, PZ0.04).
These data are highly encouraging. Even though the CI is
wide, we suggest that CgA measurement in heart failureThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Figure 3
ROC analysis illustrating the ability of chromogranin A screen, chromogranin A confirm and NT-proBNP to identify those at risk of cardiovascular death
within an elderly primary health care population during 3 years of follow-up.
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Research J P Goetze et al. Chromogranin A in heart failure 8–10 3 :54patients may have the largest clinical potential in ‘the grey
zone’ patients with natriuretic peptide levels below the
presently set diagnostic cutoff values.Limitations
As the study contains patients from a primary health care
population, the majority do not have objective signs of
impaired cardiac function in spite of prevailing symptoms
in all patients. However, the cohort does represent the truehttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0017
 2014 The authors
Published by Bioscientifica Ltdpopulation of elderly patients that general practitioners
face in clinical practice. We therefore believe that the
obtained information regarding CgA is interesting and
applicable to a primary health care population. The
evaluated population is also limited in age span, and it is
thus not possible without uncertainties to extrapolate into
another age group. However, the choice of age group was
based on the fact that this age group is the most common
among those that the general practitioner meets with the
corresponding signs/symptoms.This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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EC-14-0017.Declaration of interest
The authors declare that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the research reported.Funding
The study was supported by grants from The County Council of O¨stergo¨t-
land, the Swedish Heart and Lung Foundation, the University of Linko¨ping
(U Alehagen), and ‘Rigshospitalets Forskningsra˚d’ (J P Goetze). The funding
organizations had no role in the design, management, analyses, and
interpretation of the data, preparation, review, or approval of the
manuscript.Author contribution statement
Dr U Alehagen had full access to all of the data in the study and takes
responsibility for the data integrity and the accuracy of the data analyses.
Study concept and design: J P Goetze, U Alehagen. Design and
development of CgA assays: J F Rehfeld. Acquisition of data: U Alehagen,
L M Hilsted, J P Goetze. Analysis and interpretation of data: U Alehagen,
J P Goetze. Drafting of the manuscript: J P Goetze, U Alehagen. Critical
revision of the manuscript: U Alehagen, J P Goetze, J F Rehfeld, L M Hilsted.
Statistical analysis: U Alehagen. Obtained funding: U Alehagen, J P Goetze.
Study supervision: U Alehagen, J P Goetze. Financial disclosure: None
to report.Acknowledgements
We are grateful for the expert technical assistance from Jane Lancaster
with the chromogranin A measurements.References
1 Taupenot L, Harper KL & O’Connor DT. The chromogranin–secreto-
granin family. New England Journal of Medicine 2003 348 1134–1149.
(doi:10.1056/NEJMra021405)
2 Portela-Gomes GM, Grimelius L, Wilander E & Stridsberg M. Granins
and granin-related peptides in neuroendocrine tumors. Regulatory
Peptides 2010 165 12–20. (doi:10.1016/j.regpep.2010.02.011)
3 Corti A. Chromogranin A and the tumor microenvironment. Cellular
and Molecular Neurobiology 2010 30 1163–1170. (doi:10.1007/s10571-
010-9587-8)
4 Lindholm DP & Oberg K. Biomarkers and molecular imaging in
gastroenteropancreatic neuroendocrine tumors. Hormone and Metabolic
Research 2011 43 832–837. (doi:10.1055/s-0031-1287794)
5 Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B,
Parrinello G & Corti A. Chromogranin A in heart failure; a novel
neurohumoral factor and a predictor for mortality. European Heart
Journal 2002 23 967–974. (doi:10.1053/euhj.2001.2977)
6 Omland T, Dickstein K & Syversen U. Association between plasma
chromogranin A concentration and long-term mortality after
myocardial infarction. American Journal of Medicine 2003 114 25–30.
(doi:10.1016/S0002-9343(02)01425-0)
7 Estensen ME, Hognestad A, Syversen U, Squire I, Ng L, Kjekshus J,
Dickstein K & Omland T. Prognostic value of plasmahttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0017
 2014 The authors
Published by Bioscientifica Ltdchromogranin A levels in patients with complicated myocardial
infarction. American Heart Journal 2006 152 927.e1–927.e6.
(doi:10.1016/j.ahj.2006.05.008)
8 Jansson AM, Røsjø H, Omland T, Karlsson T, Hartford M, Flyvbjerg A &
Caidahl K. Prognostic value of circulating chromogranin A levels in
acute coronary syndromes. European Heart Journal 2009 30 25–32.
(doi:10.1093/eurheartj/ehn513)
9 Røsjø H, Masson S, Latini R, Flyvbjerg A, Milani V, La Rovere MT,
Revera M, Mezzani A, Tognoni G, Tavazzi L et al. Prognostic value of
chromogranin A in chronic heart failure: data from the GISSI-Heart
Failure trial. European Journal of Heart Failure 2010 12 549–556.
(doi:10.1093/eurjhf/hfq055)
10 Glattard E, Angelone T, Strub JM, Corti A, Aunis D, Tota B, Metz-
Boutigue MH & Goumon Y. Characterization of natural vasostatin-
containing peptides in rat heart. FEBS Journal 2006 273 3311–3321.
(doi:10.1111/j.1742-4658.2006.05334.x)
11 Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC,
Bellocci F, Crea F & Maseri A. Myocardial production of chromogranin
A in human heart: a new regulatory peptide of cardiac function.
European Heart Journal 2007 28 1117–1127. (doi:10.1093/eurheartj/
ehm022)
12 Braunwald E. Biomarkers in heart failure. New England Journal of
Medicine 2008 358 2148–2159. (doi:10.1056/NEJMra0800239)
13 Jensen TB, Hilsted L & Rehfeld JF. Library of sequence-specific
radioimmunoassays for human chromogranin A. Clinical Chemistry
1999 45 549–560.
14 Alehagen U, Lindstedt G, Levin LA & Dahlstro¨m U. The risk of
cardiovascular death in elderly patients with possible heart failure.
Results from a 6-year follow-up of a Swedish primary care population.
International Journal of Cardiology 2005 100 17–27. (doi:10.1016/j.ijcard.
2004.03.031)
15 Alehagen U, Dahlstro¨m U, Rehfeld JF & Goetze JP. Association of
copeptin and N-terminal proBNP concentrations with risk of cardio-
vascular death in older patients with symptoms of heart failure.
Journal of the American Medical Association 2011 305 2088–2095.
(doi:10.1001/jama.2011.666)
16 Alehagen U, Eriksson H, Nylander E & Dahlstro¨m U. Heart failure in the
elderly. Characteristics of a Swedish primary health care population.
Heart Drug 2002 2 211–220. (doi:10.1159/000067723)
17 Jensen-Urstad K, Bouvier F, Ho¨jer J, Ruiz H, Hulting J, Samad B,
Thorstrand C & Jensen-Urstad M. Comparison of different echo-
cardiographic methods with radionuclide imaging for measuring left
ventricular ejection fraction during acute myocardial infarction treated
by thrombolytic therapy. American Journal of Cardiology 1998 81
538–544. (doi:10.1016/S0002-9149(97)00964-8)
18 van Royen N, Jaffe CC, Krumholz HM, Johnson KM, Lynch PJ, Natale D,
Atkinson P, Deman P &Wackers FJ. Comparison and reproducibility of
visual echocardiographic and quantitative radionuclide left ventricular
ejection fractions. American Journal of Cardiology 1996 77 843–850.
(doi:10.1016/S0002-9149(97)89179-5)
19 Goetze JP, Kastrup J, Pedersen F & Rehfeld JF. Quantification of pro-B-
type natriuretic peptide and its products in human plasma by use of an
analysis independent of precursor processing. Clinical Chemistry 2002
48 1035–1042.
20 Goetze JP, Hunter I, Lippert SK, Bardram L & Rehfeld JF.
Processing-independent analysis of peptide hormones and prohor-
mones in plasma. Frontiers in Bioscience 2012 17 1804–1815.
(doi:10.2741/4020)
21 Børglum T, Rehfeld JF, Drivsholm LB & Hilsted L. Processing-
independent quantitation of chromogranin A in plasma from
patients with neuroendocrine tumors and small-cell lung carcinomas.
Clinical Chemistry 2007 53 438–446. (doi:10.1373/clinchem.2006.
076158)
22 DeLong ER, DeLong DM & Clarke-Pearson DL. Comparing the areas
under two or more correlated receiver operating characteristic curves:This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Research J P Goetze et al. Chromogranin A in heart failure 10–10 3 :56a nonparametric approach. Biometrics 1988 44 837–845. (doi:10.2307/
2531595)
23 Helle KB. Chromogranins A and B and secretogranin II as prohormones
for regulatory peptides from the diffuse neuroendocrine system.
Results and Problems in Cell Differentiation 2010 50 21–44. (doi:10.1007/
400_2009_26)
24 Rehfeld JF & Goetze JP. The posttranslational phase of
gene expression: new possibilities in molecular diagnosis.
Current Molecular Medicine 2003 3 25–38. (doi:10.2174/
1566524033361717)http://www.endocrineconnections.org
DOI: 10.1530/EC-14-0017
 2014 The authors
Published by Bioscientifica Ltd25 Rehfeld JF, Gingras MH, Bardram L, Hilsted L, Goetze JP & Poitras P.
The Zollinger–Ellison syndrome and mismeasurement of gastrin.
Gastroenterology 2011 140 1444–1453. (doi:10.1053/j.gastro.
2011.01.051)
26 Spann JF Jr, Chidsey CA & Braunwald E. Reduction of cardiac stores of
norepinephrine in experimental heart failure. Science 1964 145
1439–1441. (doi:10.1126/science.145.3639.1439-a)
27 Braunwald E, Harrison DC & Chidsey CA. The heart as an
endocrine organ. American Journal of Medicine 1964 36 1–4.
(doi:10.1016/0002-9343(64)90144-5)Received in final form 31 January 2014
Accepted 10 February 2014This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
